SEC Form 10-Q filed by Amarin Corporation plc
$AMRN
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2023 | Underweight | JP Morgan | |
| 10/25/2023 | $3.00 → $1.00 | Buy → Hold | Jefferies |
| 1/6/2023 | $1.30 → $3.00 | Hold → Buy | Jefferies |
| 5/6/2022 | Neutral → Underweight | JP Morgan | |
| 5/5/2022 | $10.00 → $3.00 | Outperform → Mkt Perform | SVB Leerink |
| 5/5/2022 | $10.00 → $3.00 | Buy → Neutral | H.C. Wainwright |
| 5/4/2022 | Outperform → Market Perform | Northland Capital | |
| 2/16/2022 | $11.00 → $10.00 | Outperform | SVB Leerink |
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report third quarter 2025 financial results and conduct a conference call on Wednesday, October 29, 2025. The Company will issue a press release detailing its third quarter 2025 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call: Via telephone: Dial in within the United States: 877-545-0523 International dial in: 973-528-0016 Access Code: 459510 V
TORONTO, Oct. 14, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, in collaboration with its partner, Amarin Corporation plc (NASDAQ:AMRN) announce the presentation of scientific data at the upcoming Canadian Cardiovascular Congress ("CCC") in Quebec City, from October 23 to 26, 2025. These presentations reflect the continued commitment of HLS and Amarin to advancing the broader therapeutic potential of Icosapent Ethyl ("IPE") and Eicosapentaenoic Acid ("EPA"), further highlighting their dedication to improving cardiovascular care for appropr
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, in collaboration with its Canadian partner HLS Therapeutics, a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease (CVD), announce the presentation of scientific data at the upcoming Canadian Cardiovascular Congress (CCC), taking place in Quebec City, Quebec, Canada from October 23 to 26, 2025. These presentations reflect the continued commitment of Amarin and HLS to advancing the broader therapeutic potential of Icosapent Ethyl (IPE) and
4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
8-K - AMARIN CORP PLC\UK (0000897448) (Filer)
EFFECT - AMARIN CORP PLC\UK (0000897448) (Filer)
10-Q - AMARIN CORP PLC\UK (0000897448) (Filer)
JP Morgan resumed coverage of Amarin with a rating of Underweight
Jefferies downgraded Amarin from Buy to Hold and set a new price target of $1.00 from $3.00 previously
Jefferies upgraded Amarin from Hold to Buy and set a new price target of $3.00 from $1.30 previously
4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as a member of the Board of Directors, effective immediately. "On behalf of the board, I welcome Michael. His financial expertise, experience on other boards and, as a fellow shareholder, his shared priority to continue focusing on strategies to maximize shareholder value, make him a beneficial addition to the board at this time," said Odysseas Kostas, MD, Chairman of the Board. "I am eager to join the board and begin working with fellow directors and the s
DUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Peter Fishman has been appointed as Chief Financial Officer for the Company, effective immediately. He will be responsible for leading Amarin's global finance organization and will report directly to the Company's Chief Executive Officer, Aaron Berg. Most recently, Mr. Fishman served as the Company's Global Controller and principal financial and accounting officer. "Pete brings tremendous experience to his new role at Amarin, including most recently as a trusted advisor to our leadership team serving as principal financial and accounting officer for the Company," said
-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarin's Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as President & CEO of the Company. "On behalf of the Company's Board of Directors, I thank Pat for his contributions to Amarin, and I welcome working closely again with Aaron
SC 13G/A - AMARIN CORP PLC\UK (0000897448) (Subject)
SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)
SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report third quarter 2025 financial results and conduct a conference call on Wednesday, October 29, 2025. The Company will issue a press release detailing its third quarter 2025 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call: Via telephone: Dial in within the United States: 877-545-0523 International dial in: 973-528-0016 Access Code: 459510 V
-- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months -- -- Q2 2025 Financial Performance Reflects Incremental Progress for VASCEPA®/VAZKEPA® in Ex-U.S. Markets, and Continued Stability in U.S. Market -- -- Cash Position Sufficient to Fund Company's Future Growth Path -- DUBLIN and BRIDGEWATER, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced financial and operational results for the second quarter of 2025. "The strategic actions taken in the second quarter – our partnership with Recordati to a
DUBLIN and BRIDGEWATER, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its second quarter 2025 results and recent strategic steps followed by Q&A on Wednesday, July 30th, 2025, at 8:00 a.m. ET. The conference call with management will follow the release of the Company's second quarter 2025 financial results in the pre-market hours on July 30th. Conference Call and Webcast Information: Access to the live call: Go to the investor relations section of the Company's website at www.amarincorp.com Dial in within the Unite